Skip to main content

Health economics

Dec 2023

New health economic assessments initiated in Sweden

On December 04, 2023, the Dental and Pharmaceutical Benefits Agency initiated its work on a few more health economic assessments of Sedaconda-ACD by Sedana Medical, a disposable product for administering anesthetic gases for patients treated on a ventilator and an alternative to intravenous anesthetics as well as robotic systems for spine surgery, including ExcelsiusGPS by Globus Medical, Mazor X Stealth by Medtronic, Cirq by Brainlab. The assessments are planned to be accomplished during 2024.
Dec 2023

MTRC launched a service of digital health economic models

Market access eventually comes down to the hospital or individual payer level. Interactive digital tools are the essential instrument to present the value of medical technologies. MTRC launched a service of digital health economic models to present the clinical and economic value of medical technologies to hospital administrators and payers. MTRC combines an unparalleled knowledge of market access realities, drivers and barriers to the adoption of medical technologies, costing for healthcare services in 34 European countries, health economic technical expertise, and the capacity to develop nice-looking digital presentation tools at a moderate cost. See a live demo of the digital model on the website.
Nov 2023

Two health economic assessments released in Sweden

On November 07, 2023, the Dental and Pharmaceutical Benefits Agency (TLV) accomplished its work on health economic assessments of Intellis and WaveWriter Alpha – spinal cord stimulation systems used for the treatment of long-term, intractable pain. Overall, TLV assesses that the results uncertainty level is high.
Mar 2023

MTRC offers a cost-effective and fast approach to adapting global health economic models to European settings

MTRC is the leading provider of market access services in Europe. Since 2017 we have accomplished 700+ projects in Europe. We provide regular consulting services to 56% of top 30 med tech companies and multiple SMEs. The typical scope of model adaptation includes adjustment of epidemiological data, validation of comparator, an adaptation of resource use and cost data, and search for local utility data. MTRC has a unique ability to work on model adaptations due to its unparalleled knowledge of payment systems in 34 European countries. We worked on model adaptations in Belgium, Denmark, Finland, France, Germany, Italy, Norway, the Netherlands, Poland, Russia, Spain, Sweden, and the UK.
Mar 2023

Publications Digest: Decision-analytic modeling for early health technology assessment of medical devices - a scoping review

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Conrads-Frank et al. performed a critical review of decision-analytic modeling studies to inform early HTA for high-risk medical devices. The study presented a summary of methodological approaches, and made a number of recommendations about technical aspects of health economic analysis for medical devices.
May 2021

Report on the 2020 results of the Russian Ministry of Health released

At the beginning of April 2021, the Ministry of Health of the Russian Federation released the final report on key results of 2020 and main targets for 2021. One of the key achievements is the increased number of medical organizations licensed to conduct high-end medical care (reached 629, including 141 federal centers).
Oct 2019

Summary of the HTA, funding and innovation payment landscape for endocrine devices in Europe

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including endocrine technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for endocrine devices in Europe.